In studies, a weekly injection caused dramatic amounts of weight loss and improved other heart-related risk factors.
For treating most conditions closely linked to heart disease, a two-pronged approach works best: lifestyle changes plus medication. For obesity, however, the currently available drug options simply aren’t very effective. But that has changed with approval of Wygovy. It's a higher dose version of semaglutide, a drug originally developed to treat type 2 diabetes. The brand name
Semaglutide works by mimicking a substance called GLP-1, which is made naturally by the gut and the brain. It prods the pancreas to release insulin when blood sugar rises too high; it also reduces appetite and helps you feel full following a meal.
To continue reading this article, you must log in.
Subscribe to Harvard Health Online for immediate access to health news and information from Harvard Medical School.
- Research health conditions
- Check your symptoms
- Prepare for a doctor's visit or test
- Find the best treatments and procedures for you
- Explore options for better nutrition and exercise
I'd like to receive access to Harvard Health Online for only $4.99 a month.Sign Me Up
Already a member? Login ».
About the Author
Julie Corliss, Executive Editor, Harvard Heart Letter
As a service to our readers, Harvard Health Publishing provides access to our library of archived content. Please note the date of last review or update on all articles.
No content on this site, regardless of date, should ever be used as a substitute for direct medical advice from your doctor or other qualified clinician.